These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28598790)

  • 1. CROI 2017: Advances in Antiretroviral Therapy.
    Jones J; Taylor BS; Tieu HV; Wilkin TJ
    Top Antivir Med; 2017; 25(2):51-67. PubMed ID: 28598790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CROI 2016: Advances in Antiretroviral Therapy.
    Taylor BS; Olender SA; Tieu HV; Wilkin TJ
    Top Antivir Med; 2016; 24(1):59-81. PubMed ID: 27398863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CROI 2019: advances in antiretroviral therapy.
    Taylor BS; Tieu HV; Jones J; Wilkin TJ
    Top Antivir Med; 2019 Apr; 27(1):50-68. PubMed ID: 31137003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CROI 2013: Advances in antiretroviral therapy.
    Taylor BS; Wilkin TJ; Shalev N; Hammer SM
    Top Antivir Med; 2013; 21(2):75-89. PubMed ID: 23681962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CROI 2015: Advances in Antiretroviral Therapy.
    Olender SA; Taylor BS; Wong M; Wilkin TJ
    Top Antivir Med; 2015; 23(1):28-45. PubMed ID: 25965310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in antiretroviral therapy.
    Sobieszczyk ME; Jones J; Wilkin T; Hammer SM
    Top HIV Med; 2006; 14(1):36-62. PubMed ID: 16641526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Antiretroviral Agents: Potent Integrase Inhibitors.
    Psichogiou M; Poulakou G; Basoulis D; Paraskevis D; Markogiannakis A; Daikos GL
    Curr Pharm Des; 2017; 23(18):2552-2567. PubMed ID: 28356041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in antiretroviral therapy.
    Olender S; Wilkin TJ; Taylor BS; Hammer SM
    Top Antivir Med; 2012; 20(2):61-86. PubMed ID: 22710908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CROI 2022: advances in antiviral therapy for HIV, COVID-19, and viral hepatitis.
    Gunaratne SH; Tieu HV; Wilkin TJ; Taylor BS
    Top Antivir Med; 2022; 30(3):490-521. PubMed ID: 36347057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Initial antiretroviral therapy in HIV-infected patients].
    Cormier H; Hoen B
    Rev Prat; 2014 Oct; 64(8):1079-85. PubMed ID: 25510130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CROI 2014: Advances in antiretroviral therapy.
    Taylor BS; Shalev N; Wilkin TJ
    Top Antivir Med; 2014 May; 22(2):616-31. PubMed ID: 24901887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology.
    Pereira M; Vale N
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antiretroviral drug pipeline: prospects and implications for future treatment research.
    Flexner C; Saag M
    Curr Opin HIV AIDS; 2013 Nov; 8(6):572-8. PubMed ID: 24100879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational Antiretroviral Drugs: What is Coming Down the Pipeline.
    Gulick RM
    Top Antivir Med; 2018 Apr; 25(4):127-132. PubMed ID: 29689540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.